This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Solomonson, L. P. Articles by Halabrin, P. R. Search for Related Content PubMed PubMed Citation Articles by Solomonson, L. P. Articles by Halabrin, P. R.

Cardiac Sodium, Potassium-Adenosine Triphosphatase as a Possible Site of Adriamycin-induced Cardiotoxicity¹

Department of Biochemistry, University of South Florida, College of Medicine, Tampa, Florida 33612

Adriamycin was tested as a possible inhibitor of cardiac sodium-potassium-activated adenosine triphosphatase (Na-K-ATPase). At concentrations of 10^-4 M and lower, Adriamycin had no effect upon either ouabain-sensitive (Na-K-ATPase) or ouabain-insensitive adenosine triphosphatase activity in homogenates and microsomal fractions of cardiac tissue from several different species. Adriamycin inhibited adenosine triphosphatase activity at a concentration of 10^-3 M, but this was due to the inhibition of ouabain-insensitive adenosine triphosphatase rather than to inhibition of Na-K-ATPase. Under no condition was an inhibition of Na-K-ATPase activity by Adriamycin observed. These conditions included preincubation of the enzyme with Adriamycin, chelation of Ca²⁺, addition of reduced nicotinamide adenine dinucleotide phosphate, and variation of buffer and pH. It was concluded that Na-K-ATPase is not a likely site of Adriamycin-induced cardiotoxicity.

¹ This research was supported in part by a grant from the American Heart Association, Florida Affiliate.

² To whom requests for reprints should be addressed, at the Department of Biochemistry, University of South Florida College of Medicine, 12901 North 30th Street, Tampa, Fla. 33612.

³ Supported by an R. G. Thompson Fellowship from the American Cancer Society.

⁴ Deceased.

Received 2/ 4/80. Accepted 11/ 4/80.